2018 WSNS Annual Meeting

LOCATION CHANGE: Due to a fire at Suncadia, the WSNS Annual Meeting will be moved to the Seattle Marriott Waterfront. The meeting date and schedule will stay the same. If you have any questions, you can call Cailey Nickerson at 206-956-3631.

Seattle Marriott Waterfront
2100 Alaskan Way
Seattle, WA  98121

Marriott Valet –  $29 + tax (special group rate)
Self parking – Bell Street Pier Parking Garage – see their website for rates:  http://www.rpnw.com/lot/seattle/30-028

Updated Exhibitor Information
For shipping and to order power cord extensions for your booth, please fill out this form and email it ASAP to Auggie Symonds, Augusta.L.Symonds@marriott.com,  Event Manager at the Seattle Marriott Waterfront.

Exhibit Order form – Shipping and Electrical
You will receive a new booth number by email on 10/17, if you have not received your new booth assignment, please email Cailey Nickerson, cailey@wsma.org.



Register Now!

October 19-20, 2018

Register Now

Click here to view the meeting brochure!

Exhibitor Information

Exhibitor Registration

2018 Support Packages
2018 Exhibitor Prospectus
2018 Invite Letter
PDF Exhibitor Agreement

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Washington State Medical Association and Washington State Neurological Society. The WSMA is accredited by the ACCME to provide continuing medical education for physicians.​

The WSMA designates this Live activity for a maximum of 7.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. ​

This activity meets the criteria for up to 7.25 hour(s) of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.


2018 Regional MS Summit

The National MS Society’s annual continuing medical education conference will be held at the Bell Harbor Conference Center in Seattle, WA, Saturday, June 9. This is the premiere MS-focused conference in the region, attracting an audience of neurologists, physiatrists, nurse practitioners, physician assistants, and others involved in the search for answers to the complex questions of multiple sclerosis.

View their website to register.


Clinical Trial: Perampanel

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome.   ClinicalTrials.gov Identifier: NCT02834793

Inclusion Criteria:
•    Participants must have a diagnosis of Lennox-Gastaut Syndrome (LGS) as evidenced by:
•    more than one type of generalized seizure, including drop seizures (atonic, tonic, or myoclonic) for at least 6 months before Visit 1;
•    an EEG reporting diagnostic criteria for LGS at some point in their history (abnormal background activity accompanied by slow, spike, and wave pattern <2.5 Hz).
•    At least 2 years old at the time of consent.
•    Have been <11 years old at the onset of LGS.
•    At least 2 drop seizures per week in the 4-week Baseline Period preceding randomization.
•    Receiving 1 to 3 concomitant AEDs at a stable dose for at least 30 days before Visit 1 (vagal nerve stimulation (VNS) and ketogenic diet do not count as AEDs).

Exclusion Criteria:
•    Presence of progressive neurological disease
•    Presence of drop seizure clusters where individual seizures cannot be reliably counted (seizure clusters are defined as ≥2 drop seizures with <5 minutes between any 2 consecutive seizures)
•    Prior treatment with perampanel with discontinuation due to safety issues (related to perampanel)
•    Prior treatment with perampanel must have been discontinued at least 30 days before Visit 1
•    Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the participant’s safety or study conduct
•    Scheduled for epilepsy-related surgery or any other form of surgery during the projected course of the study
•    Ketogenic diet and VNS, unless stable and ongoing, for at least 30 days before Visit 1

David Vossler, MD and Carole Burton RN, Rainier Clinical Research Center, Inc.
Renton, Washington, United States, 98057. Phone 1 425-251-1720

(Posted 10/06/16)